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Background: Research on the impact of depression treatment on expenditures is nascent and shows results that
vary from negative associations with healthcare expenditures to increased expenditures. However many of these
studies did not include psychotherapy as part of the depression treatment. None of these studies included “no
treatment” as a comparison group. In addition, no study has included a broad group of chronic physical conditions
in studying depression treatment expenditures.
Objective: We determined the association between depression treatment and short-term healthcare expenditures
using a nationally representative sample of Medicare beneficiaries with chronic physical conditions and depression.
Method: In this retrospective cohort study, we examined the association between depression treatment in the
baseline year and healthcare expenditures in the following year using data from 2000 through 2005 of the
Medicare Current Beneficiary Survey (MCBS), a nationally representative survey of Medicare beneficiaries. Using the
rotating panel design of MCBS, we derived five two-year cohorts: 2000–2001, 2001–2002, 2002–2003, 2003–2004,
and 2004–2005. The study sample included 1,055 elderly Medicare beneficiaries aged 65 or over. We compared
healthcare expenditures of no depression treatment group with depression treatment groups using t-tests. Linear
regressions of log-transformed dollars were used to assess the relationship between depression treatment and
healthcare expenditures after controlling for demographic, socio-economic, health status, lifestyle risk factors, year
of observation and baseline expenditures.
Results: Compared to no depression treatment ($16,795), the average total expenditures were higher for those
who used antidepressants only ($17,425) and those who used psychotherapy with or without antidepressants
($19,733). After controlling for the independent variables, antidepressant use and psychotherapy with or without
antidepressants were associated with 20.2% (95% CI: 14.1-26.7%) and 29.4% (95% CI: 18.8-41.0%) increase in total
expenditures, respectively. We observed that depression treatment was positively associated with inpatient, medical
provider and prescription drug expenditures.
Conclusion: Among the elderly Medicare beneficiaries with chronic physical conditions, depression treatment was
associated with greater short-term healthcare expenditures. Future research needs to replicate these findings and
also examine whether depression treatment reduces expenditures over a longer period of time.
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Research on how depression treatment influences health-
care expenditures among individuals with co-occurring
depression and chronic physical conditions such as dia-
betes, heart disease, and others is an emerging area of
research. In many of these chronic conditions, depres-
sion is associated with higher expenditures and treating
depression may be one pathway to reduced healthcare
expenditures with chronic physical conditions and de-
pression [1]. However, findings from studies that exam-
ined the association between depression treatment and
healthcare expenditures have produced mixed results.
Both negative and positive associations between depres-
sion treatment and healthcare expenditures have been
reported [2]. Among adults with diabetes, a randomized
control trial was conducted to compare systematic de-
pression treatment program to collaborative care with
usual care. Findings from this trial revealed that systematic
depression treatment significantly increased time free of
depression and resulted in economic benefits from the
insurer’s perspective [3]. In a single disease framework,
among veterans with diabetes, depression treatment was
associated with reduced total healthcare expenditures
[4]. A study on collaborative care for individuals with
depression and poorly controlled chronic physical con-
ditions such as diabetes and/or coronary heart disease
concluded that collaborative care improved chronic care
outcomes such as glycated hemoglobin, low-density lipo-
protein (LDL) cholesterol, and systolic blood-pressure
levels in these patients [5]. These findings suggest that
depression treatment may reduce healthcare expendi-
tures through improvement in chronic care outcomes
or reduction of depressive symptoms.
Other studies found increased healthcare expenditures
with depression treatment [6]. A stepped collaborative
care program for individuals with depression in primary
care settings resulted in substantial increases in treat-
ment effectiveness defined as depression free days and
moderate increases in expenditures [6]. A systematic
review of randomized economic evaluations concluded
that although collaborative/case management approach
for depression may improve outcomes, such approaches
may be expected to increase cost and will require initial
investment [7].
It has to be acknowledged that these studies have
contributed to the emerging literature on the association
between depression treatment and healthcare expendi-
tures among individuals with chronic conditions. However
many of these studies did not include psychotherapy as
part of the depression treatment. None of these studies
included “no treatment” as a comparison group. It is
possible that depression treatment may be delayed due
to either competing demands of physical conditions
[8-10] or watchful waiting due to adverse effects ofantidepressants on incident diabetes and heart disease
[11,12] or high rates of treatment failures and lack of
robust evidence of depression treatment on chronic
care outcomes [13,14]. In addition, the focus of these
studies were on evaluating specific programs of col-
laborative care. However, many individuals seek care
in usual-care settings and an evaluation of depression
treatment on healthcare expenditures in real-world practice
settings is needed.
Therefore, the primary objective of the study is to
analyze the association between depression treatment and
healthcare expenditures among individuals with chronic
conditions and seeking care in real-world practice settings.
Based on evidence from existing studies, we hypothesize
that there is a positive association between depression
treatment and short-term expenditures among individuals
with chronic conditions. The current study makes a
unique contribution by including a broad group of chronic
physical conditions, analyzing the major modalities of de-
pression treatment: antidepressant use and psychotherapy,
and including a group of individuals who did not receive
depression treatment. Our study findings can inform the
new emerging policy area of comparative effectiveness
which focuses on comparing alternative methods of treat-
ment in real world settings to improve both individual
and population health. For purposes of the current study
we used longitudinal data on a nationally representative




The current paper examines the association between
depression treatment and healthcare expenditures. It is
plausible to have a host of factors that are associated
with healthcare expenditures. Therefore, to guide our
selection of variables that may affect healthcare expen-
ditures, we used the expanded behavioral model on use
of health services proposed by Andersen [15]. Briefly,
the model posits that utilization of health services var-
ies as a function of 1) each individual’s unique predis-
position for using services (predisposing factors), which
includes gender, race, age, and observation year in our
study; 2) the means available to each individual for
obtaining services (enabling factors), which includes
marital status, education, poverty status, and prescrip-
tion drug coverage in our study; 3) each individual’s
level of need, which includes perceived health status
and functional status in our study; 4) personal health
practices and use of health services, including smoking
status, body mass index (BMI), depression treatment,
and the baseline year log-transformed health expendi-
tures in our study; and 5) the external environment,
which is metro status in this study.
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This is a retrospective cohort study that examined the
association between depression treatment and short-term
healthcare expenditures. In our study, we captured de-
pression treatment in the first (baseline) year; and
measured short-term expenditures as healthcare expendi-
tures in the second (follow-up) year, because antidepres-
sants have been shown to be effective after 4–5 weeks and
their effect can persist up to 18 weeks [16]. We refer to
the first year as the baseline year and the second year as
the follow-up year.
Data source
To examine the direction and magnitude of association
between depression treatment and healthcare expendi-
tures, data from multiple years of the Cost and Use files
of the Medicare Current Beneficiary Survey (MCBS) were
used. The current study uses data from the Cost and Use
files for years 2000 through 2005, the most recent years
of observation available at the time of the study. The
MCBS is an ongoing, multipurpose survey of a repre-
sentative sample of the Medicare population. It is a
unique and comprehensive source of information on the
health status, healthcare use, health insurance coverage,
and socioeconomic and demographic characteristics
of Medicare beneficiaries [17]. The MCBS combines
information from beneficiary interviews with data from
Medicare claims. The MCBS has a rotating panel design
in which survey respondents were interviewed 12 times
over a period of 4 years to get complete information for
3 years [17]. We used this rotating panel design to our
advantage and captured depression treatment in the
baseline year and examined expenditures in the subse-
quent follow-up year. As a result our study includes
five cohorts: 2000–2001; 2001–2002; 2002–2003; 2003–
2004; and 2004–2005. Although it is possible to have
repeated observations on some characteristics of the
beneficiaries from different modules of the survey (e.g.,
race was surveyed in two modules), we included only
one set of longitudinal data for each Medicare benefi-
ciary as we expect most of the repeated information to
be duplicate.
Identification of depression
Depression diagnosis is based on International Classifica-
tion of Diseases, 9th Edition, Clinical Modification (ICD-9-
CM) codes extracted from the Medicare claims. Primary
and secondary diagnostic codes were used to identify
beneficiaries who received a diagnosis of depression from
one of their providers during a healthcare encounter. We
followed HEDIS guidelines in identifying depression [18]
and included the following ICD-9-CM codes: 296.2 (major
depressive disorder, single episode), 296.3 (major de-
pressive disorder, recurrent episode), 309.1 (prolongeddepressive reaction), 300.4 (neurotic depression), and
311 (depression, not elsewhere classified). These codes
have been used to identify diagnosed depression in prior
published studies [19-22].
Presence of chronic physical conditions
Based on self-reports from the survey data, we defined
the presence or absence of each of the following chronic
physical conditions: arthritis, diabetes, respiratory diseases
including asthma, chronic obstructive pulmonary disease,
heart disease, hypertension, osteoporosis, and stroke. For
example, based on positive response to queries on whether
a doctor told the patient whether he/she had diabetes,
we classified respondents as having diabetes.
Analytical sample
Our analytical sample was based on Medicare beneficiaries
who were diagnosed with depression during the baseline
year and reported any one or more of the chronic physical
conditions listed in the previous paragraph. We further
restricted our analytical sample to Medicare beneficiaries
who were 65 and older, community-dwelling during the
observation period, were followed for 3 years, and were
enrolled in Medicare Fee-for-Service (FFS) plans because
claims are available only for FFS beneficiaries and not
for services provided through Medicare managed care
plans. After all our exclusions, our final sample consisted
of 1055 person years with depression and at least one
chronic condition.
Measures
Dependent variables: log--transformed healthcare expenditures
The MCBS combines healthcare expenditures from many
sources. These include payments made by third-party
payers including Medicare, Medicaid, Medicare-Health
Maintenance Organizations (HMO), Veterans Affairs Health
Insurance, private HMO, individually purchased insur-
ance, employer-sponsored insurance, other payers and
those paid by self or family. In addition to total healthcare,
we also analyze sub-types of expenditures, which included
inpatient, outpatient, medical providers, prescription, and
other. Other expenditures consisted of home health, vision,
dental, and durable medical equipment. In all analyses
expenditures were adjusted for medical care services
inflation and reported in 2005 dollars. We used the
annual consumer price index for medical care services
provided by the Bureau of Labor Statistics [23].
Key independent variable: depression treatment
Any antidepressant use Indicators for each respondent
were created, based on self-report, whether they had any
use of antidepressants (both brands and generics) during
the calendar year in which a diagnosis of depression took
place. Drugs included in the class of antidepressants were
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ramine, doxepin, imipramine, isocarboxazid, maprotiline,
nefazodone, nortriptyline, phenelzine, protriptyline, tranyl-
cypromine, trazodone, trimipramine, and venlafaxine, as
well as the SSRIs, which included fluoxetine, fluvoxamine,
paroxetine, and sertraline.
Psychotherapy Use of psychotherapy was identified by
using physician’s current procedure terminology (Physician’s
Current Procedural Terminology, CPT ) and Health Care
Financing Administration Common Procedure Coding
System (HCPCS) codes in the Medicare claims. Psycho-
therapy was defined broadly based on a complied list of
CPT and HCPCS codes reviewed by psychologists and
psychiatrists [22].
Other independent variables
Predisposing characteristics were: gender (women/men),
race (White, African American, other), age (categorized
as 65–69, 70–74, 75–79, and 80 years and over) and
year of observation (2000–2001, 2001–2002, 2002–2003,
2003–2004, 2004–2005). Enabling characteristics included
marital status (married, other), education (less than high
school, high school, some college, college), poverty status
measured as income to poverty ratio or federal poverty
level (less than 200% and greater than or equal to 200%)
and prescription drug coverage (yes and no). Need charac-
teristics included two variables: perceived health status
(excellent or very good, good, fair or poor) and functional
status, which is the number of activities of daily living
(ADLs) with limitations (none, 1–2 limitations, 3–6 limi-
tations). Personal health practices and use of health ser-
vices included smoking status (current, past, never), BMI
(under weight or normal, i.e., BMI <25 kg/m2, overweight,
i.e., BMI ≥25- 29.9 kg/m2, obese, i.e. BMI ≥ 30 kg/ m2)
[24], and baseline year log-transformed health expendi-
tures [25]. External environment was captured by metro
status (metro, not metro).
The reference group for the independent variables were:
gender (men), race (white), age (65–69 years), year of
observation (2004–2005), marital status (married), edu-
cation (college), poverty status (greater than or equal to
200%), prescription drug coverage (yes), health status
(excellent or very good), functional status (no ADL limi-
tations), smoking status (never), and BMI (obese).
Statistical analysis
Chi-square tests were used to test unadjusted group
differences in depression treatment. Chi-squares were
derived from performing two-way tabulations of depres-
sion treatment and subject characteristics with surveyfreq
procedures in SAS. To compare the differences in average
healthcare expenditures between no depression treat-
ment and treatment groups we used t-tests. Separatelinear regression models for each type of expenditures
with ordinary least squares (OLS) estimation were em-
ployed to assess the relationship between depression
treatment and healthcare expenditures after controlling
for predisposing, enabling, need, personal health prac-
tices and health services use, and external environment
factors. In these multiple linear regressions, healthcare
expenditures were transformed using natural logarithm
to normalize the error distribution. Point estimates of
the coefficients of continuous independent variables
on the log of monthly expenditures multiplied by 100
can be interpreted as percentage change for each unit
of change in the independent variable. The effect of
dummy variables on healthcare expenditures in terms of
percentage of expenditures can be estimated by expo-
nentiating the regression coefficients of dummy variables
subtracting one (i.e., percent change=eβ-1) and then
multiplying by 100 [26]. All tests were two-sided, and
the significant level was set at 0.05.
All analyses were conducted using survey procedures
(i.e., svyfreq, svymeans and svyreg) and in SAS 9.3 (SAS
Institute, Cary NC) in order to account for the complex
survey design of the MCBS. In these procedures domain
statement or appropriate SAS syntax was used to con-
duct analysis on the sub-group of elderly individuals
with depression. For example, the MCBS file contains
weights for each of the beneficiaries in the data set.
These weights reflect the overall selection probability of
each sample person and include adjustment for survey
nonresponse and post-stratification to control totals based
on accretion status, gender, age, race, region, and metro-
politan area status. In addition to the ongoing continuous
sampling and rotating panel design, the MCBS over-
samples persons over the age of 80 to ensure annual
sample yields are enough to produce statistically reliable
data. Therefore, in the current study we report weighed
percentages and all our analyses appropriately used SAS
survey procedures.
Results
The description of the study sample by depression treat-
ment categories is summarized in Table 1. Because of the
complex survey design of the MCBS, we report weighted
percentages in this table. Only elderly individuals who
were enrolled in fee-for-service Medicare for the full year
and did not die during the observation period were in-
cluded. Therefore medical claims for each patient in every
cohort were available for the entire 24 month period.
Statistically significant differences in depression treat-
ment rates were found by race, metro status, educational
level, and poverty status. A significantly lower percent of
African Americans (39.5%) compared to whites (55.2%)
used antidepressants only. A significantly higher percent
of individuals living in metro areas (53.7%) compared to
Table 1 Description of study sample by type of depression treatment, medicare current beneficiary survey, 2000-2005a
AD only Psych Tx (with or w/o AD) No Tx.
N Wt % N Wt % N Wt %
Observation years
2000-2001 70 42.2 34 23 60 34.7
2001-2002 113 59.4 28 14.4 54 26.3
2002-2003 104 48.5 41 19.9 69 31.6
2003-2004 132 59.8 33 14.4 55 25.8
2004-2005 137 53.3 45 18 80 28.7
Gender
Female 409 53.2 137 18.4 228 28.4
Male 147 53.5 44 15.5 90 30.9
Race
White 487 55.2 145 16.8 258 28.0
African American 24 39.5 12 22.5 23 37.9
Other 45 43.5 24 23.0 37 33.4
Age in years
65-69 111 53 36 19 59 28
70-74 119 57.4 36 17.4 55 25.1
75-79 110 51 42 19.4 63 29.6
80 + 216 52.1 67 15.7 141 32.2
Marital status
Married 239 55.8 68 16.6 118 27.6
Other 317 51.5 112 18.3 200 30.2
Metro status
Metro 397 53.7 145 19.6 211 26.7
Not Metro 159 52 36 11.9 107 36.1
Education
LT High school 176 52.7 50 14.1 121 33.2
High school 218 53.2 58 14.9 128 31.9
Some college 68 49.7 30 22.8 38 27.5
College 91 57.5 43 27.3 29 15.2
Poverty status
LT 200% 314 51 95 15.7 214 33.4
GE 200% 242 56.4 86 20.4 104 23.2
Prescription drug coverage
Yes 446 54.2 146 17.9 243 27.9
No 110 49.4 35 16.5 75 34.1
Perceived health status
Excellent/very good 137 50.4 53 20.4 81 29.2
Good 194 54.7 60 17.6 105 27.7
Fair/poor 221 53.9 67 16.1 129 30.0
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Table 1 Description of study sample by type of depression treatment, medicare current beneficiary survey, 2000-2005a
(Continued)
Functional status (ADL)
None 285 50.8 95 18.2 179 31.1
1-2 162 54.5 53 16.8 91 28.7
3-6 106 58.4 33 18.1 47 23.4
Smoking status
Current 57 53.2 17 18.6 31 28.2
Past 263 54.0 82 16.6 155 29.3
Never 235 52.8 82 18.8 128 28.4
BMI
Underweight/normal 237 52.4 84 19.5 140 28.2
Overweight 178 52.4 54 14.9 111 32.7
Obese 137 55.9 42 18.6 64 25.6
Note: Based on 1,055 elderly community-dwelling Medicare beneficiaries aged 65 years or older, and followed for one year during 2001 through 2005. All characteristics
and depression treatment were measured in year 1.
aDue to small number of individuals who received only psychotherapy but no antidepressant treatment, we combined people having psychotherapy with and
without antidepressant treatment into one group.
Wt.: Weighted. LT: Less than; GE: Greater than or equal to; Tx: Treatment; AD: Antidepressants; Psych Tx (with or w/o AD): Psychotherapy with or without
antidepressants; ADL: Activities of daily living; BMI: Body Mass Index.
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Psychotherapy with or without antidepressants was more
likely among individuals living in metro (19.6%) versus
non metro areas (11.9%). A significantly higher propor-
tion of college graduates (57.5%) used antidepressants
compared to those with a less than high school (52.7%),
high school (53.2%) and some college (49.7%) level of
education. Psychotherapy was also more common among
college graduates (27.3%) compared to those with an edu-
cation less than high school (14.1%), high school (14.9%)
or just some college (22.8%).
The average expenditures for different categories (i.e.
total, inpatient, outpatient, medical provider, prescrip-
tion drugs, and other) and standard deviations by de-
pression treatment groups are presented in Table 2. TheTable 2 Weighted average expenditures and standard deviat
medicare current beneficiary survey, 2000-2005a
Expenditures Antidepressants only
Mean $ SD $ p-value
Total 17,425 18,038.4 0.296
Inpatient 5,186 9,514.8 0.471
Outpatient 1,764 3,459.4 0.229
Medical provider 4,767 4,854.4 < 0.001
Prescription drugs 2,848 1,911.0 < 0.001
Other 2,530 9,510.6 < 0.001
Note: Based on 1,055 elderly community-dwelling Medicare beneficiaries aged 65 y
Expenditures were measured in the follow-up year and depression treatment was m
expenditures by depression treatment compared to no depression treatment based
aDue to small number of individuals who received only psychotherapy but no antid
without antidepressant treatment into one group.
p: p-value; SD: Standard Deviation; Tx: Treatment; AD: Antidepressants; Psych Tx (wiomnibus F-test showed p-values less than 0.001 with
31 degrees of freedom for all the above categories of
expenditures. Overall, compared to no depression treat-
ment ($16,795) average total expenditures were higher
for those who used antidepressants only ($17,425), a dif-
ference of $630. However, this difference was not statisti-
cally significant. Compared to no depression treatment,
those who used psychotherapy with or without antide-
pressants had higher average total expenditures ($19,733),
a difference of $2,938. This difference was statistically
significant (p = .005). When examined by type of ex-
penditures, we did not observe statistically significant
differences in average inpatient expenditures and out-
patient expenditures by depression treatment categories
(Table 2). However, for medical provider and prescriptionions by type of depression treatment and gender,
Psych Tx (with or w/o AD) No treatment
Mean $ SD $ p-value Mean $ SD $
19,733 18,448.7 0.005 16,795 17,956.7
5,142 9,510.3 0.604 5,473 9,546.1
1,653 3,449.8 0.859 1,617 3,447.1
5,839 5,130.9 < 0.001 4,295 4,774.9
3,076 2,001.2 < 0.001 1,829 1,689.9
3,656 9,498.9 0.352 3,330 9,493.8
ears or older, and followed for one year during 2001 through 2005.
easured in year 1. p-values can be used to identify statistically differences in
on t-tests.
epressant treatment, we combined people having psychotherapy with and
th or w/o AD): Psychotherapy with or without antidepressants.
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with or without antidepressants had the highest expendi-
tures followed by those who used antidepressants only for
depression treatment, and those without any treatment
for depression. For example, the average prescriptions
drug expenditures (i.e. all drugs including antidepressants)
were $3,076, $2,848, and $1829 respectively.
The percent increase or decrease associated with de-
pression treatment categories (antidepressant use only
and psychotherapy with and without antidepressants)
compared to no depression treatment and 95% CI of
these percentages for total, inpatient, outpatient, med-
ical provider, prescription drugs, and other expenditures
from separate linear regressions of log-transformed ex-
penditures using OLS method are presented in Table 3.
In the regressions after controlling for gender, race, age,
marital status, metro status, education, poverty status,
prescription drug coverage, health status, smoking sta-
tus, BMI categories, year of observation and baseline
log-transformed expenditures, total expenditures were
significantly higher for those who used antidepressants
only and psychotherapy with or without antidepressants
compared to no depression treatment. Specifically, com-
pared to no depression treatment, total expenditures
were 20.2% (95% CI: 14.1-26.7%) greater for those with
only antidepressants and 29.4% (95% CI: 18.8-41.0%)
greater for those who used psychotherapy with or with-
out antidepressants.
Inpatient expenditures were 31.4% (95% CI: 7.5-60.7%)
higher for those treated with antidepressants only and
56.9% (95% CI: 7.2-129.5%) higher for those treated with
psychotherapy with or without antidepressants compared
to no treatment. Medical provider expenditures were
greater for those treated with antidepressants only, 17.6%
(95% CI: 12.1-23.5%) and 28.6% (95% CI: 18.7-39.3%)Table 3 Percent change, 95% confidence intervals of percent
Group = No Depression Treatment) multiple linear regression
beneficiary survey, 2000 – 2005
Expenditures Antidepressants only
% Change 95% CI p
Total 20.2 [14.1 , 26.7]
Inpatient 31.4 [7.5 , 60.7]
Outpatient 11.1 [−2.4 , 26.3]
Medical provider 17.6 [12.1 , 23.5]
Prescription drug 26.8 [18.9 , 35.2]
Other −6.8 [−20.6, 9.4]
Note: Based on 1,055 community-dwelling elderly aged 65 years or older, and follo
the follow-up year and depression treatment was measured in the baseline year.
Percent changes of healthcare expenditures for depression treatment categories we
inpatient, outpatient, medical provider, prescription drugs, and other expenditures
adjusted for other independent variables: predisposing (gender, race, age, year of o
drug coverage), need (health status, functional status), personal health practices (sm
expenditures), and external environment (metro status) factors.
Tx: Treatment; AD: Antidepressants; Psych Tx(with or w/o AD): Psychotherapy with ohigher for those treated with psychotherapy with or
without antidepressants compared to no treatment. Simi-
larly, prescription drug expenditures were 26.8% (95% CI:
18.9-35.2%) greater for those treated with antidepres-
sants only and 31.2% (95% CI: 20.2-43.2%) higher for
those treated with psychotherapy with or without anti-
depressants compared to those with no treatment.
Discussion
Our study examined the association between depression
treatment and short-term expenditures among the elderly
with depression and chronic physical conditions such as
arthritis, diabetes, respiratory diseases including asthma,
chronic obstructive pulmonary disease, heart disease,
hypertension, osteoporosis, and stroke. We found that
among elderly Medicare beneficiaries with depression,
those who received depression treatment had significantly
greater total expenditures compared to those who did not
receive any treatment for depression. These results are
consistent with some studies in which treatment for de-
pression was associated with greater expenditures [6,7].
Although, Simon and colleagues included all individuals
who received some form of treatment for depression,
their comparison was between collaborative care and
usual care [6].
It is not surprising that depression treatment was asso-
ciated with greater total healthcare expenditures in the
short-term. It is possible to have chronic depression that
can last for several years. There is some evidence of per-
sistent depression in the general population and among
those with persistent depression an overwhelming major-
ity (87%) also had a chronic condition. Among veterans
with diabetes, heart disease, and hypertension, 5.6% were
diagnosed with persistent depression [27] The STAR*D
(Sequenced Treatment Alternatives to Relieve Depression)change depression treatment categories (Reference
s of log-transformed dollars (2005 $), medicare current
Psych Tx (with or w/o AD)
-value % Change 95% CI p-value
<0.001 29.4 [18.8 , 41.0] <0.001
0.008 56.9 [7.2 , 129.5] 0.021
0.112 28.1 [ 0.0 , 64.2] 0.051
<0.001 28.6 [18.7 , 39.3] <0.001
<0.001 31.2 [20.2 , 43.2] <0.001
0.389 13.5 [−15.2 , 51.9] 0.396
wed for one year during 2001 through 2005. Expenditures were measured in
re calculated from parameter estimates from separate regressions on total,
which included dental, vision, and durable medical equipment. The models
bservation), enabling (marital status, education, poverty status, prescription
oking status, body mass index), healthcare use (baseline year log-transformed
r without antidepressants.
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health conditions, revealed that relapse rates could be as
high as 50% even among individuals who were in remis-
sion in a stepped treatment approach [28,29]. Even the
ENRICHD (Enhancing Recovery In Coronary Heart Dis-
ease) trial which focused on nonpharmacologic treatment
of depression, in patients with myocardial infarction as
well as depression and/or low perceived social support,
showed that psychological outcomes (reduced score on the
Beck Depression Inventory scale) improved at six months
but did not last up to 30 months [15].
Greater short-term expenditures among those with
depression treatment compared to those without any
depression treatment could be due to early discontinu-
ation of medications. In one study of a large private
health insurance database, total healthcare expenditures
for individuals, with equal distribution of comorbid con-
ditions, who used antidepressants for 3 months were
significantly lower than expenditures of those who dis-
continued the medications early [30]. Using healthcare
claims from 30 health plans, Katon and colleagues ana-
lyzed the relationship between adherence to depression
treatment and total medical charges among specific
chronic conditions. This study found that adherence to
depression treatment reduced total medical charges
[31]. However, our study could not measure adherence
to depression treatment due to unavailability of date
of pharmacy claims. Our study included elderly with
co-occurring depression any number of chronic condi-
tions. The presence of chronic diseases may be associ-
ated with or induce biological changes that render
otherwise useful treatments for depression ineffective
[29]. Indeed, the SADHART (Sertraline Antidepressant
Heart Attack Randomized Trial) trial compared anti-
depressant treatment against placebo in depressed patients
with acute myocardial infarction or unstable angina and
did not report any significant difference in the incidence
of severe cardiac events (death, myocardial infarction,
congestive heart failure, stroke, and recurrent angina)
between the antidepressant group and those who re-
ceived a placebo [13]. Among individuals with chronic
conditions, even when depression treatment is success-
ful the ENRICHD trial revealed that depression treat-
ment did not decrease the risk of event free survival
after an MI [14]. In a confirmatory analysis of previously
unanalyzed cohort, the STAR*D trial found that individuals
with medical conditions and major depressive disorder
were a particularly disadvantaged group with significant
challenges to clinical management [32]. Thus, it is pos-
sible that among individuals with co-occurring depres-
sion and chronic conditions, the relationship between
depression treatment and expenditures may be complex
and may not reveal a reduction in expenditures in the
short-term. Our results, therefore, suggest the need forexamining the association between depression treat-
ment and healthcare expenditures using a longer period
of follow-up.
For each type of medical care services, we found a statis-
tically significant relationship between depression treatment
and healthcare expenditures except for the “outpatient” and
“other” categories. Further research is needed as to whether
adequate depression treatment may reduce inpatient ex-
penditures because studies in the veterans administration
and elsewhere have documented that among individuals
with depression, those who had adequate duration of anti-
depressants were less likely to be hospitalized than those
who did not have adequate duration [33]. Similarly, Katon
and colleagues reported that in individuals with poorly
controlled diabetes, coronary heart disease, or both and
coexisting depression, collaborative care produced posi-
tive outcomes for chronic care and this may indirectly
lead to reduced inpatient care for depression [5]. In this
study we could not assesses adequate depression treat-
ment due to lack of information on prescription dates
or whether collaborative care was provided.
We observed significantly higher expenditures in pre-
scription drug expenditures for those who received de-
pression treatment compared to those who did not. This
may be due to the fact that prescription drug expendi-
tures in our study may also include payments for antide-
pressants as the main modality for treatment in our
sample. One could also speculate that those who use anti-
depressants may also be using other medications for con-
ditions that are comorbid with depression (e.g., anxiety).
The findings from the current study have to be consid-
ered in the context of its strengths and limitations. The
study had many strengths such as longitudinal study design,
nationally representative sample of the elderly, inclusion of
psychotherapy use with or without antidepressants, com-
prehensive list of independent variables, and complete
utilization that included both Medicare and non-Medicare
expenditures. We also derived depression from diagnosis
codes of inpatient and outpatient claims. Limitations of the
study are recall bias because some data were queried only
in the survey. For example, antidepressant use was based
on self-reports because prescription drug was not covered
by Medicare during our study period. However to minimize
recall errors, the MCBS had put in place many steps such
as requesting the respondents to bring their prescription
bottles, facilitating recording of all their healthcare events,
and the list of medications used in the previous rounds by
the respondent to the interviewers. In addition, we did
not measure discontinuation of depression treatment
which may be associated with greater short-term healthcare
expenditures. Although depression diagnosis was derived
from claims and may indicate clinical need; by using diag-
nosed depression, we may have excluded individuals for
whom depression diagnoses was not coded. Our study was
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have unmeasured confounding factors. For example, indi-
viduals in depression treatment groups may systematically
differ from those without treatment on unobserved and
unmeasured characteristics such as preferences and mo-
tivation that could explain some of the relationship be-
tween depression treatment and healthcare expenditures.
Finally, due to the lack of individuals in our study period
who reported being on both an antidepressant and were
involved in psychotherapeutic treatment, we were not able
to fully evaluate costs related to such combined treatment.
Conclusion
Despite these limitations our study contributed to the nas-
cent literature on the relationship between depression
treatment and healthcare expenditures in individuals with
chronic physical conditions. Among individuals treated
with either antidepressants or psychotherapy, depression
treatment was associated with greater short-term expendi-
tures. For example, individuals having antidepressants
use only had 20% increase in total expenditures com-
pared to those with no treatment; while individuals hav-
ing psychotherapy with or without antidepressants had
a 31% increase. Similarly, medical provider expenditures
were 17.6% higher for those treated with antidepressants
only compared to those with no treatment for depression.
Our study findings highlight the need for future studies
that include longer follow-up period and the need to con-
trol for treatment-resistant depression.
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